Welcome to Seroba's December 2020 newsletter with all our latest news.
Fusion To Partner with AstraZeneca
Fusion has announced a partnership with AstraZeneca to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer.
Together, the companies will discover, develop and commercialize novel targeting therapies, which will utilize Fusion’s Fast-Clear™ linker technology platform with antibodies in AstraZeneca’s oncology portfolio.
Read more
A Third Love Story?
Heidi Zak (pictured left), co-founder and CEO of ThirdLove, is set to take on an advisory role in the acceleration of Atlantic Therapeutic's INNOVO® brand. Heidi's company, ThirdLove, is famous for having transformed the way women choose and buy bras. Heidi herself has been recognized in Fortune's 40 Under 40, EY Entrepreneur of the Year and Goldman Sachs' 100 Most Intriguing Entrepreneurs.
Susan Trent, the new CEO at Atlantic Therapeutics, said "Heidi knows how to change the conversation and she is keen to help INNOVO® disrupt the huge Stress Urinary Incontinence category - one in which millions of women are being told that their only option is to just live with bladder leaks." Read more.
INNOVO is busy sharing the good news that there is now another option. See the game-changing U.S. advertising, as introduced here by CEO, Susan Trent.
Nothing Short of Outstanding!
"I find these results nothing short of outstanding!" Those were the words of Dr E. Armstrong, MD, Professor of Medicine-Cardiology at the University of Colorado School of Medicine. He was speaking at the release of 24-Month data from the PQ Bypass DETOUR1 Trial for Percutaneous Femoropopliteal Bypass at the VIVA 2020 Virtual Conference. See the results of the clinical trial which focused on an advanced new treatment for complex Peripheral Artery Disease here.
Storm Force
STORM Therapeutics is busy making waves as the pioneer in its field. The company has selected STC-15 for development towards first in human clinical studies.
STC-15 is an orally bioavailable, small molecule METTL3 inhibitor targeting an entirely new mechanism of action (modulation of RNA epigenetics) to treat acute myeloid leukaemia (AML) and other solid and haematological cancers. Read more
The candidate, STC-15 was selected with support from Evotec's novel Drug Discovery Engine. Read more
Separately, FutureNeuro in Dublin has partnered with STORM to explore the role of RNA epigenetics in epilepsy. Read more
Meet the Entrepreneur
One in five people will develop Heart Failure during their lifetime and 50% of patients die within 5 years of diagnosis. Endotronix is developing a heart failure management system designed to help the patient and their doctor manage heart failure more effectively. As part of our 'Meet the Entrepreneur' series, we talk to the founder and CEO of Endotronix, Harry Rowland. Read more.
Virtually Yours
Seroba's website has recently undergone a makeover. We've also added a new video section. Each video is bite-size - just one or two minutes long. They answer questions like 'What is Epigenetics?' or 'What's the sensation like when you're wearing INNOVO Shorts?'
Why not drop in sometime and discover the answers on our Seroba Website Forum.
Unmasking the IPO Market
In this issue's thought leadership piece, Peter reflects on the global IPO market and how it has fared during the pandemic. Read more
'Tis the Season
'Tis the Season to be jolly, jolly careful. But, it's also a time to be thankful.
We in Seroba would like to thank all the wonderful frontline staff who worked tirelessly to help others during 2020. We'd also like to send a huge thank you to everyone in the global life sciences industry working so hard to bring forward vaccines, therapeutics and diagnostics, in record time, to give us all a better future.